Chen Wei, academician of the Chinese Academy of Engineering and researcher of the Academy of Military Sciences, was awarded the national honorary title of "People's Hero" on the 11th. In order to fight the epidemic, she led the team to develop a recombinant new crown vaccine, and took the lead in entering phase I and phase II clinical trials in China and internationally, verifying the safety and immunogenicity of the vaccine.

　　According to the latest news released by CCTV, the Phase III international clinical trial of the vaccine is progressing in an orderly manner.

　　A CCTV reporter recently interviewed Academician Chen Wei. She said that vaccines are for healthy people, so safety comes first. The team has done a lot of research to verify that clinical safety risks are minimized. "I have used all the 18 martial arts accumulated over decades. Although the pressure is great, we have faith and confidence!"

　　On January 26, Chen Wei was ordered to lead a military medical expert team to Wuhan urgently, leading the team to focus on the pathogen transmission mutation of the new coronavirus, rapid detection technology, and vaccine antibody development.

　　On March 16, the new coronavirus vaccine developed by Chen Wei led the scientific research team became the first vaccine approved to enter clinical trials in China.

　　On April 10, 108 volunteers who completed the first phase of the vaccine clinical trial inoculation, all finished intensive medical observation and were in good health.

　　On April 12, the vaccine launched a phase II clinical trial, with a total of 508 volunteers participating, becoming the only new coronavirus vaccine in the world that entered the phase II clinical trial at that time.

　　On July 20, the results of the Phase II clinical trial of the recombinant new crown vaccine (adenovirus vector) developed by Chen Wei's team were released, becoming the world's first officially published Phase II clinical trial data of the new crown vaccine. The test results showed that after 28 days of a single vaccination, 99.5% of the subjects developed specific antibodies, 95.3% of the subjects developed neutralizing antibodies, and 89% of the subjects developed specific T cell immune responses. This shows that the new crown vaccine developed by Chen Wei's team can provide "triple protection" to healthy people and "keep the new crown virus out". According to my country's "Vaccine Management Law", the vaccine has met the technical requirements for emergency use.

　　Many vaccines developed in China are in Phase III

　　On the 6th, WHO held a routine press conference for new coronary pneumonia. Michael Ryan, the head of WHO's health emergency project, said that at that time, there were about 165 vaccines in the trial stage, 26 were in clinical trials, and six were in the third stage. In the phase of clinical trials, three of which are from China, it is incredible to achieve such results in a short time.

　　Among them, the inactivated vaccine developed by Sinopharm Sino Biotech has entered the phase III clinical trial stage and has the capacity for mass production.

　　According to a report from the Global Times on July 16, China’s bio-produced new coronavirus inactivated vaccine inventory reached more than 4 million copies, and this number is still rising. Once China’s bio-new coronavirus inactivated vaccine completes Phase III clinical trials After the trial is approved for listing, it can quickly meet the huge domestic demand for vaccination.

　　In addition, Sinopharm Sinopharm has established high-level biosafety production facilities in two biological product research institutes in Beijing and Wuhan. After the production workshops of these two research institutes are put into use, China Bio will be able to ensure that the total annual production capacity of the new crown vaccine will reach 220 million doses.

　　Source: China Youth Daily Comprehensive CCTV Military, China Youth Daily